Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

NEXT STORY
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
PREV STORY
iXensor to close the loop of COVID-19 outbreak prevention with the fully digitalized rapid antigen test and an encrypted mobile pass
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Discuva Awarded Innovate UK Grant to Develop New Antibiotics to Address Multidrug Resistance

CAMBRIDGE, UK, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Discuva, the antibiotics drug discovery and ...

author_avatar
NASDAQ Market News

JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016

Minneapolis, MN, Feb. 21, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device ...

author_avatar
NASDAQ Market News

MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018

Hoersholm, Denmark, June 1, 2018 - Medical Prognosis Institute A/S ("MPI") hereby announces that ...

author_avatar
NASDAQ Market News